NASDAQ: HALO
Last close prices updated as of
Jun 05, 2023, 1:03 PM EST
| USD | BATS BZX Real-Time Price
- Last Close 33.57
- Sector Healthcare
- Industry Biotechnology
- Investment Style Small Growth
- Day Range 32.85 – 33.90
- Year Range 29.85 – 59.46
- Market Cap 4.4482 Bil
- Volume / Avg 300,152.0 / 1.6 Mil
- Price / Sales 6.66
- Price / Book 67.13
- Forward Div Yield —
- Trailing Div Yield —
Morningstar‘s Stock Analysis HALO
Valuation
Currency in —
Is it the right time to buy or sell?
Is it the right time to buy or sell?
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
About Quantitative Ratings
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Unlock Our Full Analysis With Morningstar Investor
Company Profile HALO
Business Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.
Halozyme Therapeutics Inc
XNAS: HALO
| Transgene SA
XPAR: TNG
| Rubius Therapeutics Inc
PINX: RUBY
| Immunogen Inc
XNAS: IMGN
| |
Price
| 33.78 | 2.22 | 0.02 | 15.11 |
Currency
| USD | EUR | USD | USD |
Change
| +$0.21 (0.63%) | +$0.40 (21.98%) | $0.00 (11.93%) | +$0.74 (5.11%) |
Market Cap
| 4.45 Bil | 222.45 Mil | 1.74 Mil | 3.40 Bil |
Industry
| Biotechnology | Biotechnology | Biotechnology | Biotechnology |
Sector
|
Healthcare
|
Healthcare
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for Halozyme Therapeutics Inc Stock
No. HALO does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
HALO’s market cap is 4.45 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
HALO’s stock style is Small Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
HALO’s price/sales is 6.66.
Price/sales represents the amount an investor is willing to pay for a dollar generated from
a particular company’s sales or revenues.
HALO’s price/forward earnings is 25.63.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates.
The lower the Forward P/E, the cheaper the stock.
HALO’s price/book is 67.12.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets,
based on historical, rather than current, valuations. Historical valuations generally do not reflect
a company’s current market value. Value investors frequently look for companies that have low price/book ratios.
See HALO’s valuation ratios compared to the Market Index.
HALO’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare HALO’s historical performance against its industry peers and the overall market.